MCID: VRL003
MIFTS: 43

Variola Major

Categories: Infectious diseases, Skin diseases

Aliases & Classifications for Variola Major

MalaCards integrated aliases for Variola Major:

Name: Variola Major 12 15 71
Smallpox 71

Classifications:



External Ids:

Disease Ontology 12 DOID:0050508
ICD9CM 34 050.0
SNOMED-CT 67 47452006
UMLS 71 C0037354 C1812609

Summaries for Variola Major

Disease Ontology : 12 A smallpox that results in severe infection, located in skin, has material basis in Variola virus. The infection results in formation of lesions.

MalaCards based summary : Variola Major, also known as smallpox, is related to chickenpox and smallpox, and has symptoms including fever, pruritus and exanthema. An important gene associated with Variola Major is DUSP14 (Dual Specificity Phosphatase 14), and among its related pathways/superpathways are Signal transduction_Erk Interactions- Inhibition of Erk and Primary immunodeficiency. The drugs Antiviral Agents and Iron-Dextran Complex have been mentioned in the context of this disorder. Affiliated tissues include skin, t cells and testes.

Wikipedia : 74 Smallpox was an infectious disease caused by one of two virus variants, Variola major and Variola minor.... more...

Related Diseases for Variola Major

Diseases related to Variola Major via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 122)
# Related Disease Score Top Affiliating Genes
1 chickenpox 29.7 CD8A CD4
2 smallpox 11.9
3 variola minor 11.7
4 vaccinia 10.5
5 cork-handlers' disease 10.1 CD8A CD4
6 ventilation pneumonitis 10.1 CD8A CD4
7 diffuse infiltrative lymphocytosis syndrome 10.1 CD8A CD4
8 diabetes mellitus, insulin-dependent, 23 10.1 CD8A CD4
9 autoimmune lymphoproliferative syndrome, type iia 10.1 CD8A CD4
10 early yaws 10.1 CD8A CD4
11 bird fancier's lung 10.1 CD8A CD4
12 parapsoriasis 10.1 CD8A CD4
13 norwegian scabies 10.1 CD8A CD4
14 skin sarcoidosis 10.1 CD8A CD4
15 follicular mucinosis 10.1 CD8A CD4
16 viral exanthem 10.1 CD8A CD4
17 tertiary syphilis 10.1 CD8A CD4
18 spongiotic dermatitis 10.1 CD8A CD4
19 acute retinal necrosis syndrome 10.1 CD8A CD4
20 invasive malignant thymoma 10.1 CD8A CD4
21 metal allergy 10.1 CD8A CD4
22 cerebritis 10.1 CD8A CD4
23 granulomatous hepatitis 10.0 CD8A CD4
24 acute interstitial pneumonia 10.0 CD8A CD4
25 oral hairy leukoplakia 10.0 CD8A CD4
26 superficial basal cell carcinoma 10.0 CD8A CD4
27 secondary syphilis 10.0 CD8A CD4
28 glanders 10.0 CD8A CD4
29 parotid disease 10.0 CD8A CD4
30 nickel allergic contact dermatitis 10.0 CD8A CD4
31 neurosarcoidosis 10.0 CD8A CD4
32 esophageal candidiasis 10.0 CD8A CD4
33 myeloid and lymphoid neoplasms associated with fgfr1 abnormalities 10.0 CD8A CD4
34 cardiomyopathy, familial hypertrophic, 9 10.0 CD8A CD4
35 oral tuberculosis 10.0 CD8A CD4
36 pneumonic tularemia 10.0 CD8A CD4
37 tularemia 10.0 CD8A CD4
38 farmer's lung 10.0 CD8A CD4
39 pneumonic plague 10.0 CD8A CD4
40 adenoid hypertrophy 10.0 CD8A CD4
41 dacryoadenitis 10.0 CD8A CD4
42 duodenitis 10.0 CD8A CD4
43 combat disorder 10.0 CD8A CD4
44 xerophthalmia 10.0 CD8A CD4
45 good syndrome 10.0 CD8A CD4
46 miliary tuberculosis 10.0 CD8A CD4
47 iritis 10.0 CD8A CD4
48 cryptogenic organizing pneumonia 10.0 CD8A CD4
49 retinitis pigmentosa 46 10.0 CD8A CD4
50 mucocutaneous leishmaniasis 10.0 CD8A CD4

Graphical network of the top 20 diseases related to Variola Major:



Diseases related to Variola Major

Symptoms & Phenotypes for Variola Major

UMLS symptoms related to Variola Major:


fever, pruritus, exanthema

Drugs & Therapeutics for Variola Major

Drugs for Variola Major (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 34)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Antiviral Agents Phase 4
2 Iron-Dextran Complex Phase 3
3
Phenol Approved, Experimental Phase 2 108-95-2 996
4
tannic acid Approved Phase 1, Phase 2 1401-55-4
5
Benzocaine Approved, Investigational Phase 1, Phase 2 94-09-7, 1994-09-7 2337
6
rituximab Approved Phase 2 174722-31-7 10201696
7
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
8
BCG vaccine Investigational Phase 1, Phase 2
9 Heptavalent Pneumococcal Conjugate Vaccine Phase 2
10 Vaccines Phase 1, Phase 2
11 Immunologic Factors Phase 2
12 Immunoglobulins Phase 2
13 Antibodies Phase 2
14 Immunoglobulins, Intravenous Phase 2
15 Rho(D) Immune Globulin Phase 2
16 gamma-Globulins Phase 2
17 Immunosuppressive Agents Phase 2
18 Isoantibodies Phase 2
19 Thymoglobulin Phase 2
20 Antirheumatic Agents Phase 2
21 Antineoplastic Agents, Immunological Phase 2
22 Antilymphocyte Serum Phase 2
23
Metronidazole Approved Phase 1 443-48-1 4173
24 Pharmaceutical Solutions Phase 1
25 Keyhole-limpet hemocyanin Phase 1
26 polysaccharide-K Phase 1
27 interferons Phase 1
28 Poly ICLC Phase 1
29 Androgens Phase 1
30 Anti-Retroviral Agents Phase 1
31 Anti-Bacterial Agents
32 Anti-Infective Agents
33 Interferon-gamma
34 Analgesics, Opioid

Interventional clinical trials:

(show top 50) (show all 109)
# Name Status NCT ID Phase Drugs
1 A Special Access Program for the Prophylactic Vaccination With IMVAMUNE® for Personnel Working Directly With or in the Vicinity of Replicating Vaccinia Virus Completed NCT03472014 Phase 4
2 A Post Marketing Study of the Safety, Tolerability, and Pharmacokinetics of TPOXX In Adult Subjects Weighing More Than 120 KG Completed NCT04392739 Phase 4 Tpoxx
3 Vaccinia Vaccination (ACAM2000®) of Plasma Donors for the Production of Vaccinia Immune Globulin Intravenous (VIGIV) Recruiting NCT02443623 Phase 4
4 An Open-label, Single Arm, Phase III Clinical Study to Evaluate the Efficacy and Safety of CJ Smallpox Vaccine in Vaccinia-naive Healthy Volunteers Completed NCT01056770 Phase 3 smallpox vaccine CJ-50300
5 An Open-label, Single Arm, Phase III Clinical Study to Evaluate the Efficacy and Safety of CJ Smallpox Vaccine in Previously Vaccinated Healthy Volunteers Completed NCT01317238 Phase 3 smallpox vaccine CJ-50300
6 Randomized, Double Blind, a Phase II/III Clinical Trial to Evaluate the Efficacy and Safety of CJ-50300 in Healthy Volunteers Completed NCT00607243 Phase 2, Phase 3
7 An Expanded Double-Blind, Placebo Controlled, Multicenter Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti Orthopoxvirus Compound Tecovirimat When Administered Orally for 14 Days in Subjects Completed NCT02474589 Phase 3 tecovirimat
8 Vaccinia Vaccine (ACAM2000) for the Production of Vaccinia Immune Globulin Intravenous (VIGIV) Completed NCT01158157 Phase 3
9 A Randomized, Double-Blind, Placebo-Controlled Phase III Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-Naïve Subjects Completed NCT01144637 Phase 3
10 A Randomized, Open-label Phase III Non-inferiority Trial to Compare Indicators of Efficacy for MVA-BN® Smallpox Vaccine to ACAM2000® in 18-42 Year Old Healthy Vaccinia-naïve Subjects Completed NCT01913353 Phase 3
11 An Open-label, Single Arm Study to Provide Additional Information on Safety and Effectiveness of rVSVΔG-ZEBOV-GP Completed NCT03161366 Phase 3
12 An Open-Label Prospective Cohort Study of IMVAMUNE® Smallpox Vaccine in Adult Healthcare Personnel at Risk for Monkeypox in the Democratic Republic of the Congo Recruiting NCT02977715 Phase 3
13 A Randomized, Double-blind, Multicenter Phase III Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of a Freeze-dried Formulation of MVA-BN® Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects Active, not recruiting NCT03699124 Phase 3
14 A Phase I/II Clinical Trial to Evaluate the Safety and Immunogenicity of LC16m8, A Modified Vaccinia Vaccine, in Healthy Volunteers Unknown status NCT00103584 Phase 1, Phase 2
15 Comparison of Safety and Immunogenicity of a High Dose (5 x 10^8 TCID50) and a Standard Dose (1 x 10^8 TCID50) of IMVAMUNE® in Healthy Vaccinia-Naive Individuals Completed NCT00879762 Phase 2 Placebo
16 Take Evaluation and Safety of Smallpox Vaccine (LISTER Strain) in Naïve Healthy Adults. Completed NCT00258947 Phase 2
17 A Multicenter, Open-label Phase I/II Study to Evaluate Safety and Immunogenicity of MVA-BN® Smallpox Vaccine in HIV Infected Subjects (CD4 Counts >350 / µl) and Healthy Subjects With and Without Previous Smallpox Vaccination Completed NCT00189904 Phase 1, Phase 2
18 A Multicenter, Open-label, Controlled Phase II Study to Evaluate Immunogenicity and Safety of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in 18-40 Year Old Subjects With Diagnosed Atopic Dermatitis Completed NCT00316602 Phase 2
19 A Randomized, Double-blind, Multicenter Phase II Trial to Compare the Immunogenicity and Safety of a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects Completed NCT01668537 Phase 2
20 A Double Blind, Randomized Dose Response Study of Dryvax Vaccine Against Smallpox in Previously Vaccinated Adults Completed NCT00032708 Phase 2
21 Phase II, Double-blind, Randomised, Dose-finding Study to Evaluate the Immunogenicity of Three Different Doses of MVA-BN Smallpox Vaccine in 18-30 Year Old Smallpox naïve Healthy Subjects Completed NCT00189956 Phase 2
22 A Multicenter, Double-Blind, Randomized Dose-Response Study of Dryvax Vaccine Against Smallpox in Previously Unvaccinated Adults Completed NCT00026611 Phase 2
23 A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects Completed NCT00857493 Phase 2
24 Double-Blind, Placebo-Controlled, Dose-Finding, Phase 2 Study Assessing Safety, Tolerability, Immunogenicity of Three Dose Levels of ACAM3000 Modified Vaccinia Ankara Smallpox Vaccine in Adults With and Without Previous Smallpox Vaccination Completed NCT00466245 Phase 2 MVA Smallpox vaccine;Placebo
25 Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine When Increasing the Number of Injections Compared to the Standard Regimen in Immunocompromised Subjects With HIV Infection Completed NCT02038881 Phase 2
26 The Effect of Dose On Safety, Tolerability, and Immunogenicity of ACAM2000 Smallpox Vaccine in Adults Without Previous Smallpox Vaccination Completed NCT00053495 Phase 2
27 A Multicenter, Open-label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA-BN® (IMVAMUNE) Smallpox Vaccine in 18-55 Year Old Naive and Previously Vaccinated HIV Infected Subjects With CD4 Counts >200 - 750/µl. Completed NCT00316589 Phase 2
28 A Partially Randomized, Partially Double-blind, Placebo-controlled Phase II Non-inferiority Study to Evaluate Immunogenicity and Safety of One and Two Doses of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in 18-55 Year Old Healthy Subjects Completed NCT00316524 Phase 2
29 The Effect of Dose on Safety, Tolerability, and Immunogenicity of ACAM2000 Smallpox Vaccine in Adults With Previous Smallpox Vaccination Completed NCT00053482 Phase 2
30 A Multicenter, Double-Blind, Randomized Study of the Safety and Efficacy of Aventis Pasteur's Smallpox Vaccine, USP (APSV) in Vaccinia-Naive Adults. Completed NCT00050518 Phase 2
31 An Open-Label Phase II Study to Evaluate Immunogenicity and Safety of a Single IMVAMUNE Booster Vaccination Two Years After the Last IMVAMUNE Vaccination in Former POX-MVA-005 Vaccinees Completed NCT00686582 Phase 2
32 ACAM 3000 MVA (Acambis Modified Vaccinia Ankara) Immunization Followed by Dryvax® Vaccination of Healthy Vaccinia-Naïve Adults: A Phase I/II, Placebo-Controlled Study of the Effects of Dose and Route of Administration of MVA on Safety, Reactogenicity and Immunogenicity, Followed by Dryvax® Immunization to Assess Effects of MVA Vaccination on Dryvax® Takes Completed NCT00133575 Phase 1, Phase 2
33 A Comparison of Dressing Preparations for Smallpox Vaccination Sites With a Focus Upon the Risk of Secondary Transmission of Vaccinia Virus Completed NCT00063856 Phase 1, Phase 2
34 A Phase I/II Study to Evaluate the Safety and Preliminary Efficacy of Various Concentrations of Aventis Pasteur's Smallpox Vaccine, USP (APSV) in Vaccinia-naive Adults Completed NCT00038987 Phase 1, Phase 2
35 A Multicenter, Double Blind, Randomized Dose-response Study of Dryvax Vaccine Against Smallpox in Previously Vaccinated Adults Completed NCT00050505 Phase 2
36 Evaluation and Treatment of Ocular Complications of Vaccinia Vaccination: Suitability of NP-016 Vaccinia Immune Globulin (VIG) for Sight-Threatening Conditions [VIG31] Completed NCT00081835 Phase 2 NP-016 Vaccine Immune Globulin (IV-VIG)
37 Comparison of the Safety and Immunogenicity of Lyophilized IMVAMUNE® (1x10^8 TCID50) Versus Liquid Formulation IMVAMUNE® (1x10^8 TCID50) Administered by the Subcutaneous Route and a Lower Dose Liquid Formulation IMVAMUNE® (2x10^7 TCID50) Administered by the Intradermal Route in Healthy Vaccinia-Naïve Individuals Completed NCT00914732 Phase 2
38 Evaluation of IMVAMUNE® Smallpox Vaccine With Respect to Safety and Optimization of Immune Responses by Different Vaccination Regimens in Vaccinia-Naïve Adults Completed NCT00437021 Phase 1, Phase 2 Placebo (subcutaneous);Placebo (scarification)
39 A Phase II, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of IMVAMUNE® Using Three Immunization Schedules and Two Modes of Delivery Completed NCT01827371 Phase 2
40 Double-Blind, Randomized, Placebo-Controlled, Multi-Center Trial to Assess Safety, Tolerability, and PK of the Anti-Orthopoxvirus Compound ST-246 When Administered as a Single Daily Oral Dose for 14 Days in Volunteers in the Fed State Completed NCT00907803 Phase 2 ST-246 400 mg;ST-246 600 mg;Placebo
41 Phase II Trial of a WT-1 Analog Peptide Vaccine in Patients in Complete Remission (CR) From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL) Completed NCT01266083 Phase 2
42 A Study of the Systemic and Cutaneous Immune Responses to Yellow Fever Vaccination in Atopic Dermatitis Subjects Completed NCT00723489 Phase 1, Phase 2 YFV-17D Placebo
43 Assessment of Protection Against Malaria by Sporozoite Challenge of Healthy Adults Vaccinated With AdCh63 ME-TRAP and MVA ME-TRAP Completed NCT00890760 Phase 1, Phase 2
44 A Randomized Phase II Study of a PSA-Based Vaccine in Patients With Localized Prostate Cancer Receiving Standard Radiotherapy Completed NCT00005916 Phase 2 rV-PSA;rF-PSA;rV-B7.1
45 A Phase II Study Evaluating the Safety and Immunogenicity of a New TB Vaccine, MVA85A, in Healthy Children and Infants After BCG Vaccination at Birth Completed NCT00679159 Phase 2
46 Open Label, Dose Escalation and Age De-escalation for ChAdOx1 85A in Ugandan Adults and Adolescents, Followed by a Phase IIa Randomised, Open-label Trial Among Adolescents Comparing ChAdOx1 85A Prime Followed by MVA 85A Boost Versus BCG Re-vaccination. Recruiting NCT03681860 Phase 1, Phase 2
47 MVA-BN Imvamune Smallpox Vaccine Virus for Treatment of Basal Cell Carcinoma, Squamous Cell Carcinomas Not yet recruiting NCT04410874 Phase 1, Phase 2
48 The Effect of Dose On Safety, Tolerability, and Immunogenicity of ACAM1000 Smallpox Vaccine in Adults Without Previous Smallpox Vaccination A Phase 2, Randomized, Double-Blind, Dose-Response Study Terminated NCT00053508 Phase 2
49 Multi-Drug Desensitization Protocol for Heart Transplant Candidates Terminated NCT01556347 Phase 2 Bortezomib, Thymoglobulin, Rituximab, Gamimune N, (IVIG), Plasmapheresis
50 MVA-BN (IMVAMUNE®) Immunization in Persons Who Have Undergone Prior Hematopoietic Stem Cell Transplant (HSCT): A Phase I, Placebo-Controlled Study of the Safety, Reactogenicity and Immunogenicity of MVA Immunization Completed NCT00565929 Phase 1 Placebo

Search NIH Clinical Center for Variola Major

Genetic Tests for Variola Major

Anatomical Context for Variola Major

The Foundational Model of Anatomy Ontology organs/tissues related to Variola Major:

19
Skin

MalaCards organs/tissues related to Variola Major:

40
Skin, T Cells, Testes, Prostate, Breast, Bone, Eye

Publications for Variola Major

Articles related to Variola Major:

(show top 50) (show all 6938)
# Title Authors PMID Year
1
TNF deficiency dysregulates inflammatory cytokine production, leading to lung pathology and death during respiratory poxvirus infection. 61
32571912 2020
2
EPPIC (Efficient Purification by Parental Inducer Constraint) Platform for Rapid Generation of Recombinant Vaccinia Viruses. 61
32346550 2020
3
COVID-19 and Other Pandemics: How Might They Be Prevented? 61
32478500 2020
4
Early smallpox vaccine manufacturing in the United States: Introduction of the "animal vaccine" in 1870, establishment of "vaccine farms", and the beginnings of the vaccine industry. 61
32473878 2020
5
The future of vaccine development. 61
31443989 2020
6
Contagious Diseases and its Consequences in the Late Qajar Period Mashhad (1892-1921). 61
32536181 2020
7
Harm as a Necessary Component of the Concept of Medical Disorder: Reply to Muckler and Taylor. 61
32437578 2020
8
Understanding the Anemic Global Response to COVID-19. 61
32464668 2020
9
Finding a way to address a wicked problem: vaccines, vaccination, and a shared understanding. 61
31799892 2020
10
Rapid, Seamless Generation of Recombinant Poxviruses using Host Range and Visual Selection. 61
32510495 2020
11
Magnitude and diversity of immune response to vaccinia virus is dependent on route of administration. 61
32174514 2020
12
Serological Immunity to Smallpox in New South Wales, Australia. 61
32443405 2020
13
Human monkeypox - After 40 years, an unintended consequence of smallpox eradication. 61
32417140 2020
14
Successful smallpox eradication: what can we learn to control COVID-19? 61
32478398 2020
15
With regard to the bicentennial of the independence of Colombia: Reading practices of Antonio Nariño and the development of a presumably effective vaccine against smallpox 61
32463602 2020
16
[THE PSYCHOLOGICAL IMPACT OF COVID-19 ON MENTAL HEALTH - LITERATURE REVIEW]. 61
32431119 2020
17
Reevaluating the Risk of Smallpox Reemergence. 61
32373931 2020
18
HLA genes in Amerindians from Mexico San Vicente Tancuayalab Teenek/Huastecos. 61
32209242 2020
19
Brincidofovir: understanding its unique profile and potential role against adenovirus and other viral infections. 61
32166967 2020
20
How health care providers should address vaccine hesitancy in the clinical setting: Evidence for presumptive language in making a strong recommendation. 61
32242766 2020
21
Potential of live pathogen vaccines for defeating the COVID-19 pandemic: History and mechanism. 61
32320059 2020
22
Smallpox Vaccine and Resident Responses in Modern Shanghai: Focusing on Regional and Cultural Comparison. 61
32418978 2020
23
Rethinking the History of Smallpox in the Early Twentieth Century: The SS Korea and Uncertainty Surrounding the Diagnosis of Smallpox. 61
32418982 2020
24
Imported Monkeypox, Singapore. 61
32338590 2020
25
Plagues, pandemics and epidemics in Irish history prior to COVID-19 (coronavirus): what can we learn? 61
32404230 2020
26
High risk genotypes for schizophrenia may have been adaptive in the context of smallpox. 61
31935637 2020
27
Assessing a syndemic: Gibraltar in the time of cholera. 61
32312531 2020
28
[Colleges of royal physicians and isolation hospitals to control public hygiene in Chile from 1879 to 1920]. 61
32191681 2020
29
Safety of Administering Live Vaccines During Pregnancy: A Systematic Review and Meta-Analysis of Pregnancy Outcomes. 61
32168941 2020
30
A Modified Vaccine against Smallpox. Reply. 61
32212534 2020
31
Drug Development against Smallpox: Present and Future. 61
31932370 2020
32
Three different paths to introduce the smallpox vaccine in early 19th century United States. 61
32057569 2020
33
A randomized phase II trial to compare safety and immunogenicity of the MVA-BN smallpox vaccine at various doses in adults with a history of AIDS. 61
32057574 2020
34
A Modified Vaccine against Smallpox. 61
32212533 2020
35
The Falconi's needle against anti-vaccination: A minimally invasive tool in the nineteenth century. 61
31928854 2020
36
Reanalysis of Alzheimer's brain sequencing data reveals absence of purported HHV6A and HHV7. 61
32336252 2020
37
[Vaccine hesitancy in Spain (1801), Ruiz de Luzuriaga responses in defense of vaccination]. 61
32051392 2020
38
WHO celebrates 40 years since eradication of smallpox. 61
32006510 2020
39
Evidence of vaccinia dissemination despite lack of major reaction following smallpox vaccination. 61
31899026 2020
40
Study of Antiviral Activity of Metabolites of a New Serratia species K-57 Strain. 61
32147764 2020
41
Erythema multiforme, Stevens Johnson syndrome, and toxic epidermal necrolysis reported after vaccination, 1999-2017. 61
31870573 2020
42
Repair of a previously uncharacterized second host-range gene contributes to full replication of modified vaccinia virus Ankara (MVA) in human cells. 61
32019881 2020
43
Loss of Resistance to Mousepox during Chronic Lymphocytic Choriomeningitis Virus Infection Is Associated with Impaired T-Cell Responses and Can Be Rescued by Immunization. 61
31826990 2020
44
Humanized Mice for Live-Attenuated Vaccine Research: From Unmet Potential to New Promises. 61
31973073 2020
45
An Ethnobotanical Study of Traditional Knowledge and Uses of Medicinal Wild Plants among the Marakwet Community in Kenya. 61
32308704 2020
46
The Prevention of Infections in Older Adults: Vaccination. 61
31613000 2020
47
Antibiotics: From the Beginning to the Future: Part 1. 61
31713213 2020
48
Discovery of Retro-1 Analogs Exhibiting Enhanced Anti-vaccinia Virus Activity. 61
32390964 2020
49
Stopping live vaccines after disease eradication may increase mortality. 61
31648913 2020
50
What Should Health Science Journalists Do in Epidemic Responses? 61
31958392 2020

Variations for Variola Major

Expression for Variola Major

Search GEO for disease gene expression data for Variola Major.

Pathways for Variola Major

Pathways related to Variola Major according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.67 DUSP7 DUSP3 DUSP1
2 10.54 CD8A CD4

GO Terms for Variola Major

Biological processes related to Variola Major according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptidyl-tyrosine dephosphorylation GO:0035335 9.63 DUSP7 DUSP3 DUSP29 DUSP22 DUSP14 DUSP1
2 inactivation of MAPK activity GO:0000188 9.56 DUSP7 DUSP3 DUSP14 DUSP1
3 protein dephosphorylation GO:0006470 9.5 STYXL2 DUSP7 DUSP3 DUSP29 DUSP22 DUSP14
4 negative regulation of MAPK cascade GO:0043409 9.46 DUSP3 DUSP1
5 negative regulation of T cell receptor signaling pathway GO:0050860 9.43 DUSP3 DUSP22
6 peptidyl-threonine dephosphorylation GO:0035970 9.4 DUSP7 DUSP1
7 negative regulation of T cell activation GO:0050868 9.37 DUSP3 DUSP22
8 peptidyl-tyrosine dephosphorylation involved in inactivation of protein kinase activity GO:1990264 9.32 DUSP3 DUSP1
9 dephosphorylation GO:0016311 9.17 STYXL2 DUSP7 DUSP3 DUSP29 DUSP22 DUSP14

Molecular functions related to Variola Major according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hydrolase activity GO:0016787 9.91 DUSP7 DUSP3 DUSP29 DUSP22 DUSP14 DUSP1
2 phosphoprotein phosphatase activity GO:0004721 9.73 DUSP7 DUSP3 DUSP29 DUSP22 DUSP14 DUSP1
3 protein tyrosine phosphatase activity GO:0004725 9.63 DUSP7 DUSP3 DUSP29 DUSP22 DUSP14 DUSP1
4 protein tyrosine kinase binding GO:1990782 9.54 DUSP3 DUSP22 CD4
5 MAP kinase tyrosine/serine/threonine phosphatase activity GO:0017017 9.5 DUSP7 DUSP14 DUSP1
6 phosphatase activity GO:0016791 9.5 STYXL2 DUSP7 DUSP3 DUSP29 DUSP22 DUSP14
7 mitogen-activated protein kinase binding GO:0051019 9.46 DUSP7 DUSP1
8 protein tyrosine/threonine phosphatase activity GO:0008330 9.4 DUSP7 DUSP1
9 protein tyrosine/serine/threonine phosphatase activity GO:0008138 9.17 STYXL2 DUSP7 DUSP3 DUSP29 DUSP22 DUSP14

Sources for Variola Major

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....